Abstract
The efficacy and tolerability of symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD) was evaluated in an open trial. Eight outpatients, aged 18-45 years and diagnosed with PMDD, were treated with 10-20 mg of citalopram from the start of premenstrual symptoms until the onset of menses. Primary efficacy variables were the premenstrual tension scale (PMTS-O) and the clinical global impression of improvement (CGI). Treatment was associated with significant improvement in PMDD symptoms (p < 0.001).
MeSH terms
-
Adult
-
Antidepressive Agents, Second-Generation / administration & dosage*
-
Citalopram / administration & dosage*
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Humans
-
Luteal Phase / drug effects
-
Middle Aged
-
Patient Satisfaction
-
Premenstrual Syndrome / drug therapy*
-
Premenstrual Syndrome / psychology
-
Psychiatric Status Rating Scales
-
Research Design
-
Selective Serotonin Reuptake Inhibitors / administration & dosage*
-
Treatment Outcome
Substances
-
Antidepressive Agents, Second-Generation
-
Serotonin Uptake Inhibitors
-
Citalopram